The growth and dissemination of tumors rely on an altered vascular network, which supports their survival and expansion and provides accessibility to the vasculature and a route of transport for metastasizing tumor cells. The remodeling of vascular structures through generation of new vessels (for example, via tumor angiogenesis) is a well studied, even if still quite poorly understood, process in human cancer. Antiangiogenic therapies have provided insight into the contribution of angiogenesis to the biology of human tumors, yet have also revealed the ease with which resistance to antiangiogenic drugs can develop, presumably involving alterations to vascular signaling mechanisms. Furthermore, cellular and/or molecular changes to pre-existing vessels could represent subtle pre-metastatic alterations to the vasculature, which are important for cancer progression. These changes, and associated molecular markers, may forecast the behavior of individual tumors and contribute to the early detection, diagnosis and prognosis of cancer. This review, which primarily focuses on the blood vasculature, explores current knowledge of how tumor vessels can be remodeled, and the cellular and molecular events responsible for this process.
INTRODUCTION
Cancer represents a dysregulation of the body's normal, controlled cellular programs. Malignant cells acquire mutations that may confer enhanced proliferation, resistance to apoptosis, or motility that allow tumors to metastasize beyond the site of origin and colonize distant organs, which is the most lethal aspect of cancer. 1 Importantly tumor cells also require the collaboration of the tumor microenvironment for growth and progression. The blood vasculature is a key component of the tumor microenvironment contributing to the classic hallmarks of cancer by undergoing angiogenesis, supporting sustained proliferative signaling in tumor cells and facilitating metastasis. 2 During embryonic development, the blood vasculature develops via a precisely regulated program involving differentiation of endothelial cells (ECs) from precursors, proliferation and vessel morphogenesis, followed by growth and branching of immature vessels, specification into vessel subtypes (e.g. arteries, veins and capillaries) and recruitment of supporting perivascular cells. 3, 4 Although some growth, remodeling and specialization of the blood vasculature occurs after birth, the adult vasculature is viewed as mature and relatively stable. The lymphatic vasculature, a unidirectional system of vessels with important roles in fluid homeostasis and immunity, originates from the cardinal vein during embryonic development, and undergoes similar processes of plexus formation, branching growth and maturation. 5 Both blood and lymphatic vascular systems are viewed as largely quiescent in adults, but can be reactivated to have a key role in supporting tumor progression. 6, 7 Angiogenesis in the adult involves remodeling of the blood vasculature into an expanded network, requiring proliferation, sprout formation, migration, adhesion, de-adhesion, recruitment and differentiation of endothelial and accessory cells. Although many features of tumor-induced angiogenesis and lymphangiogenesis recapitulate those observed in development, tumors also remodel the blood and lymphatic vessels in distinctive ways, which are not restricted to the primary tumor site. 8, 9 In this review we examine remodeling of the vasculature at the primary tumor, regional LNs and distant metastatic sites. While touching on the role of the lymphatics, we focus on the anatomical changes to the blood vasculature, as well as the cellular features of the remodeling process. Finally, we examine what these changes may tell us about the prognosis of a given tumor and its response to antiangiogenic therapy.
REQUIREMENT OF BLOOD VESSELS FOR TUMOR ESTABLISHMENT
Tumors require generation of a blood vascular supply for delivery of nutrition and oxygen, and to ensure waste removal. Hence, angiogenesis to generate tumor blood vessels is considered essential for a tumor to grow beyond a few millimeters in size. [10] [11] [12] [13] [14] The onset of the 'angiogenic switch' can precede malignant transformation of early hyperplasias, and is associated with malignant growth and metastasis. [15] [16] [17] The molecular triggers for this switch commonly derive from tumor cells, but angiogenic growth factors may also be secreted by stromal cells or cells recruited from the circulation, such as macrophages and mast cells. 18, 19 The secreted glycoprotein vascular endothelial growth factor (VEGF)-A (also known as VEGF or vascular permeability factor) was the first angiogenic factor to be identified, 20, 21 and is considered to be important for angiogenesis in a variety of tumor types, chiefly via activation of the receptor VEGFR-2 on ECs.
A prerequisite for tumor angiogenesis is the presence of responsive blood vessels in the surrounding tissue ( Figure 1 ). In non-vascularized tissues, such as the anterior chamber of the eye, 1 tumors are necessarily growth-restricted, but the same tumors can readily become vascularized and grow when transplanted into tissues containing a blood vasculature. 12, 13 Vessel subtypes are important as sprouting angiogenesis usually arises from capillaries or small vessels, rather than larger caliber vessels (arteries and veins), which tend to reside more deeply in tissue and have highly structured circumferential layers of supporting pericytes or smooth muscle cells. 3, 22 In addition to vessel subtype heterogeneity, the capillary beds of different tissues show distinct molecular and functional features that can influence tumor progression. 23 These findings indicate that features of blood vessels and of tumor cells should be considered when assessing mechanisms or likelihood of tumor progression.
VASCULAR REMODELING IN THE PRIMARY TUMOR
Features of tumor blood vessels Although tumor angiogenesis shares some features with embryonic angiogenesis, it lacks the same tight regulation and hierarchically ordered patterning. Tumor blood vessels are typically heterogeneous in nature, tortuous, poorly or irregularly branched, circumferentially enlarged and often hyperpermeable. 8, 24, 25 The reduced surface area:volume ratio of the tumor vasculature, combined with high interstitial pressure caused by vascular leakage, impairs the delivery of oxygen and nutrients and the removal of metabolites, thus perpetuating a poorly perfused tumor microenvironment typified by hypoxia and acidosis. [26] [27] [28] [29] Hypoxia-inducible factor-1 is stabilized under hypoxic conditions and initiates transcription of a suite of genes, including VEGFA, which further perpetuates unregulated angiogenesis. 28 The hypoxic and acidic tumor environment also selects for apoptosis-resistant and metastasis-competent tumor cells, 30, 31 and reduces the efficacy of radiotherapy. 32 As well as being ineffective at delivering chemotherapy, leaky tumor blood vessels are increasingly accessible to metastasizing tumor cells. 24 The tumor can thus thrive because of, rather than in spite of, its dysregulated vasculature.
The architecture of the tumor vasculature can vary according to characteristics of the tumor cells. 8, 33 For example, tumors expressing different angiogenic growth factors can induce distinct patterns of angiogenesis. [34] [35] [36] [37] [38] [39] [40] [41] Expression of the VEGF-A 165 isoform in a melanoma model resulted in an effectively perfused, finely branched capillary network characterized by abundant intraluminal bridging and supported by tortuous peripheral vessels, whereas the VEGF-A 121 isoform generated larger, more sparse vessels within necrotic tumors. 34 In a breast cancer model, expression of VEGF-A 189 resulted in an increased vascular area, characterized by dilated vessels, but the tumor growth rate was slower than that promoted by the expression of VEGF-A 165 . 42 In human oligodendrogliomas, vascular patterning can be associated with tumor progression: slow-growing grade II tumors exhibited regularly spaced, interconnected capillaries that were presumed to originate from branching angiogenesis, Figure 1 . Overview of the potential roles of the vasculature at major sites of tumor growth and spread. The arteries and veins of the blood vascular network supply oxygenated blood and remove waste products from normal tissue, while the initial lymphatic vessels remove excess cells and fluid from the interstitium. Primary tumors can develop in many organs, and therefore will be influenced by the specialized vessels present in those organs and their anatomical and histological characteristics. Although small clusters of primary tumor cells may survive from the diffusion of nutrients in the surrounding tissue, large tumor masses are dependent on tumor angiogenesis for growth and progression. Tumor blood vessels are characterized by hyperpermeability, altered molecular profiles and disrupted architecture, including detachment of pericytes. Tumor angiogenesis and lymphangiogenesis in and around the primary tumor contribute to tumor growth and spread. Tumor cells leave the primary site and arrive at regional LNs, where evidence of remodeling of HEVs, blood and lymphatic vessels has been described. Spread of tumor cells directly through blood vessels or via LNs allows the formation of distant metastases, often within metastatic niches established in specific organs, and may rely on organ-specific vessels. Key terms are illustrated in the enclosed legend.
whereas aggressive grade III tumors featured glomeruloid endothelial proliferations and larger vessels that suggested intussuscceptive vascular growth, whereby new, parallel vessels form via intraluminal division of larger vessels. 43, 44 Recently, a morphological classification of the vasculature in hepatocellular carcinoma has been reported. In the same study, a molecular classification of the tumor vasculature in clear cell renal carcinoma was also shown using staining with anti-CD34, -CD31 and -SMA antibodies. 45 Although vascular patterns in tumors differ widely, some common remodeled tumor blood vessel types have been identified. 33, 46 In tumors, and in a 'tumor surrogate' model involving adenovirally expressed VEGF-A, 47 mother vesselslarge, thin-walled, hyperpermeable and pericyte-poor vessels derived from existing small vessels-are the first to form. Expansion of the endothelial tube is enabled by detachment of pericytes and their secretion of cathepsins, which degrade the basement membrane; levels of cysteine protease inhibitors also decrease in the vicinity. 33 This allows the endothelial tube to expand not only via EC proliferation, but also expansion of the EC surface area. The endothelial plasma membrane area is augmented by vesiculo-vaculolar organelles, membranous vesicles/ vacuoles that normally reside in the cytoplasm, allowing stretching and thinning of ECs. 25, 48 Mother vessels are transient and subsequently develop into either vascular malformations, capillaries or glomeruloid microvascular proliferations. Vascular malformations resemble abnormally large veins and result from the acquisition by mother vessels of an irregular smooth muscle coat (possibly due to pericyte reattachment). 33 Capillaries can develop via intraluminal bridging of mother vessels or by branching angiogenesis. Glomeruloid microvascular proliferations resemble renal glomeruli, comprising a mass of small endothelial-lined channels with a multi-layered basement membrane and occasional perivascular cells that develop via multiple rounds of EC proliferation and intussception within the mother vessels. 49 Interestingly, glomeruloid microvascular proliferations are a better prognostic indicator of poor survival than microvessel density in melanoma, breast and prostate cancer, and are characteristic of glioblastoma. [50] [51] [52] As glomeruloid microvascular proliferations are poorly perfused and multi-layered, it seems unlikely that they would directly support metastasis; hence, they may serve as a surrogate indicator of a more aggressive tumor phenotype. Notably, the vascular malformations, capillaries, and large feeder arteries and draining veins that form later in tumor development are less sensitive to VEGF withdrawal; this may contribute to the ineffectiveness of some antiangiogenesis treatments against the vasculature of more established tumors. 8 Effect on immune infiltration Another dysfunction of tumor blood vessel endothelium relates to its ability to recruit immune cells. In spite of a strong inflammatory milieu, it has been shown that tumor ECs express reduced levels of leukocyte adhesion molecules such as E-selectin, CD34, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, and become anergic to the inflammatory cytokines that would normally upregulate expression of these receptors. 53 Treatment with antiangiogenic agents in vivo was shown to restore expression of these molecules and improve infiltration of leukocytes, including CD8 þ cytotoxic T cells, into experimental tumors. 54 High endothelial venules (HEVs), which are specialized postcapillary venules characterized by plump ECs and normally restricted to secondary lymphoid tissue, have recently been observed in many primary lesions of human melanoma and in breast, ovarian, lung and colon carcinoma, [55] [56] [57] [58] as well as in experimental models of lung metastasis and melanoma. [59] [60] [61] HEVs are strongly linked with the extent of T-lymphocyte infiltration into the primary lesions and the neogenesis of tertiary lymphoid organs at the tumor site, which had previously been shown to indicate a positive prognosis for many tumor types. 62 Furthermore, their presence was linked with regression of primary lesions and metastases in experimental models, [59] [60] [61] and represented an independent indicator of positive prognosis in breast cancer patients. 55 These emerging data strongly suggest that induction of HEVs in tumors supports increased infiltration of T lymphocytes, as well as mature dendritic cells and B cells, resulting in a robust antitumor response that can include in situ T-cell priming and activation. 59, 60 As with lymphoid tissue neogenesis in other pathologies, generation of tumor-associated HEVs is mediated by lymphotoxin a, LIGHT (tumor necrosis factor superfamily member 14) and the lymphotoxin b receptor. [59] [60] [61] Although more research is required, remodeling of tumor vasculature into HEV-type vessels could be a key to enhancing therapeutic and endogenous antitumor immunity. [59] [60] [61] [62] Lymphatic vessels Lymphatic vessels also remodel within the tumor environment 63 ( Figure 1 ). Lymphangiogenesis in and around tumors, promoted by proteins such as VEGF-C and VEGF-D, has been identified both experimentally and in human tumor samples, [64] [65] [66] and has been linked to increased metastasis. 6, 67 As some of the molecules responsible for remodeling blood vessels also act on the lymphatic system (for example, VEGFs and angiopoietins), one may expect a partially coordinated response from lymphatic and blood vessels (for review of the molecular regulation of lymphangiogenesis see Alitalo 5 ). Although most of the work has focused on alterations to initial lymphatics (that is, the smallest subtype of lymphatic vessel) in and around the tumor, recent data have shown the capacity of lymphangiogenic factors to increase the diameter of large collecting lymphatic vessels, facilitating the metastatic spread of experimental tumors. 68 Molecular profile of tumor ECs Although tumor blood vessels remodel by the physical repositioning of their cellular components, these changes are often preceded and accompanied by molecular alterations, which are potential targets for novel antiangiogeneic therapy and could aid in the diagnosis and prognosis of tumors (reviewed in Bussolati et al.
69
). More recently, screening approaches have been used to identify genes expressed by tumor endothelium and to distinguish between physiological and pathological angiogenesis. 70 Joyce et al. 71 identified stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis, whereas others used peptide homing to show progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. 72 Similar studies have also defined such molecular changes in the lymphatic endothelium. [73] [74] [75] These novel markers may be of use in designing strategies to selectively deliver drugs or imaging agents to tumor vasculature. 69 Perivascular cells Perivascular cells, in particular pericytes, are critical for maturation and stabilization of blood vessels. 22 Stable pericyte coverage seems dependent on a number of key molecular pathways, in particular the transforming growth factor-b, angiopoietin-1/Tie-2 and platelet-derived growth factor-B/platelet-derived growth factor receptor-b signaling pathways. During tumor angiogenesis, pericyte detachment is necessary to allow proliferation and migration of ECs, but also contributes to the leaky, unstable phenotype of tumor blood vessels. 76 Although tumor blood vessels devoid of pericytes are more vulnerable to antiangiogenic therapy, increased pericyte coverage can contribute to the process of 'vascular normalization,' a restoration of the normal function of blood vessels that improves delivery of chemotherapeutic and immunotherapeutic agents 24 -see later section of this review. Genetic deletion or pharmacological suppression of regulator of G-protein signaling-5, normally upregulated in tumor vessel pericytes, results in normalized vasculature and improved efficacy of tumor immunotherapy. 77, 78 Improved pericyte cover of tumor vessels is also linked with decreased metastasis, implicating a barrier function for these cells. 79 On the other hand, treatment with kinase inhibitors of platelet-derived growth factor and VEGF receptors disrupted the pericyte-invested tumor vessels, which often resist anti-VEGF-A treatment, enabling tumor regression. 80 The function of pericytes in a particular tumor context will need to be carefully considered in the design and application of future antiangiogenic therapies.
Endothelial progenitor cells
The involvement of bone marrow-derived (BMD) cells in tumor neovacularization 81 and patterning of the angiogenic tumor microenvironment [82] [83] [84] 85 However, subsequent transplantation of GFPexpressing CD31
þ CD11b þ EPCs failed to confirm any EPC involvement, 97 and despite accumulating clinical evidence for their therapeutic/diagnostic potential in angiogenesis, 81, 93, 98, 99 the identity of BMD EPCs and their role in tumor angiogenesis remains under debate. 100, 101 Although mouse strain-intrinsic differences in EPC levels 102 may explain some reported discrepancies, detailed analysis of a range of mouse models failed to reveal any EPCs in established tumor vessels. 103 While arguing against EPC involvement, this finding flagged the possibility that vascular EPC detection may depend on tumor stage; indeed, BMD genetically tagged EPCs were unambiguously confirmed in 1-20% of tumor vessel sprouts in grafted and spontaneous mouse tumors, whereby specific targeting significantly delayed tumor growth. 104 EPCs were only found in emerging vessels, and during vessel maturation were rapidly diluted by ECs to undetectable levels. The subsequent demonstration that vascularisation of metastases coincided with BMD EPC integration implicated these cells in the angiogenic switch. 105 Accordingly, vascular disrupting agents, which cause rapid tumor necrosis and hypoxia, trigger extensive BMD EPC mobilization and vascular integration into the vascular disrupting agent-resistant tumor rim, suggesting that vascular disrupting agent/antiangiogenic drug combinations may combat resistance to either therapy. 86, 106 Identification of human BMD
þ EPCs and contributing to ischemic and tumor vascularization, confirms EPCs also in human disease; 107, 108 indeed, analysis of patients receiving BM transplants from opposite sex donors before cancer onset revealed donor-derived EPCs in 4.9% of tumor vessels. 109 Overall, current evidence confirms BMD EPCs within emerging tumor vessels and indicates that they have considerable potential as therapeutic/diagnostic targets. However, the surprising lack of a unique EPC surface marker 99, [110] [111] [112] for their unambiguous detection, and ongoing disputes on extent and timing of EPC involvement, emphasize the urgency for further research defining their identity and biology.
Transdifferentiation and vascular mimicry Although existing tissue-resident blood vessels are seen as the major origin of the tumor vasculature, the transdifferentiation of other local cell types within the tumor to mimic vascular structures is a developing area of investigation. Initially identified in melanoma, 113 the differentiation of tumor cells to mimic ECs and to line the vascular channels in tumors has been reported by a number of groups. 114 Other studies have demonstrated that tissue-resident stem cells could be a source of tumor ECs from tumors originating from the kidney, 115 breast 116 and brain. 117 Cancer stem-like cells have also been reported to generate endothelium in glioblastoma. [118] [119] [120] [121] [122] Furthermore, studies have shown that perivascular cells may also be derived from tumor ECs via endothelial-to-mesenchymal transition. 123 Although the relative contribution of these processes to tumor angiogenesis in human cancers is not clear, they do provide a means whereby subsets of tumor vessels may escape the effects of antiangiogenic drugs and/or chemotherapy.
VASCULAR REMODELING IN THE SENTINEL LYMPH NODE
It is well established for many human cancers that metastatic involvement of regional lymph nodes (LNs) is an early event in cancer metastasis, has adverse prognostic significance and can be an important determinant of disease management. 124 Defining sentinel LNs (SLNs), those nodes first to receive metastatic tumor cells, has added to the prognostic value of the LN biopsy in human cancer and has reduced the need for radical LN dissection. LNs are intricately connected into both the lymphatic and blood vascular circulation to facilitate immune surveillance, and their own vasculature is highly responsive to pathological changesincluding cancer-in the surrounding tissue. 125 Although angiogenesis has been observed in LN metastases, few studies have examined in detail the changes to the blood vasculature within tumor-draining LNs. The observation that blood vessel density and proliferation rates are often comparable or positively correlated [126] [127] [128] [129] between primary tumor and SLN suggests that the angiogenicity of metastatic clones can mirror the characteristics of the primary tumor. Notably, the presence of vascular 'hotspots' in SLN metastases was found in one study to be a more powerful independent prognostic indicator of poor disease-free and overall survival than factors relating to the primary tumor. 127 HEVs represent a large component of the existing LN vasculature from which angiogenic vessels can be derived. Intriguingly, the characteristic features of these vessels can be altered by the primary tumor (Figure 2) , even before metastasis. [130] [131] [132] [133] This remodeling is typified by dilation and flattening of the characteristically 'high' endothelium, as well as a loss of important functional molecules. Proliferation and dilation of HEVs begins before the arrival of metastatic cells. 130, 131, 133 Loss of lymphocyte homing molecules such as CCL21 is also evident at the pre-metastatic stage, with a concurrent reduction in lymphocyte adhesion; 132 HEVs instead become engorged with red blood cells. 130, 134 HEVs become progressively more remodeled as metastatic deposits expand, eventually losing expression of characteristic ligands such as peripheral node addressin. 130 Lowered expression of BMP-4, recently found to be expressed in mouse HEVs, is also associated with the transition from high to flat endothelium, and a preferential proliferative response of remodeled, BMP-4-low, HEVs to tumor-expressed VEGF-D was recently observed in a xenograft mouse model. 135 Larger blood vessels in the LN are also affected, with increased adhesion of polymorphonuclear cells via upregulation of P-selectin. 132 The clinical significance of HEV remodeling remains to be determined. It has been proposed that tumor-induced remodeling of HEVs into capillary-type vessels represents preparation of the SLN as an angiogenically enriched, immune-suppressed metastatic niche. 131 Inhibition of lymphocyte trafficking into LNs may contribute to tumor-induced immunosuppression, 132, 136 and the close interaction of expanding HEVs and lymphatic vessels in SLNs suggests the capacity for a lymphatic-venous 'shortcut' into circulation for metastasizing tumor cells. 131, 137 HEV remodeling may also represent a relatively early and sensitive response to tumor activity, as the normal HEV phenotype is highly dependent on lymphatic drainage and various immune cell subsets, which are typically disturbed by the presence of a tumor. 138, 139 The strong interdependence between the LN blood and lymphatic vasculature, and the immune system, thus needs to be taken into account when investigating the mechanisms and consequences of tumor-induced remodeling of the LN vasculature.
Not surprisingly, the lymphatics of the SLN are also remodeled by the primary tumor. Dilation, proliferation and expansion of the lymphatic network in tumor-draining LNs often begin before the arrival of metastatic cells, 130, 133, 140, 141 and increase in line with the metastatic load. 142, 143 In mouse models, pre-metastatic LN lymphangiogenesis increases lymph flow to the draining and next sequential LN, [144] [145] [146] and lymphangiogenesis within involved SLNs is associated with distant LN and lung metastasis. 147, 148 Links between elevated SLN lymphangiogenesis or lymphatic invasion and distant LN metastasis have also been observed in human breast and pancreatic cancer and in extra-mammary Paget's disease. 142, 143, 149, 150 Furthermore, lymphangiogenesis in tumordraining LNs can independently predict non-SLN metastasis and lower disease-free survival in rectal and breast cancer, even when the lymphatic vessel density in the primary tumor shows no association. 149, 151, 152 VEGFs are strongly implicated in LN lymphangiogenesis-elevated levels of VEGF-A in primary breast tumors predicted LN lymphatic and also blood vascular EC proliferation rates; futhermore, expression of VEGF-A or VEGF-C is linked with LN lymphangiogenesis in human oral squamous cell carcinoma, lung and breast cancer, 133, 140 and in experimental models. 147, 148 Specific interactions between tumor cells and the LN microenvironment have also been identified-expression of stromal cell-derived factor-1 in tumor and LN lymphatics may provide a chemotactic impetus for CXCR4 þ invasive cells in extramammary Paget's disease, 143 whereas bulk emboli of breast cancer cells were seen to invade LN lymphatic vessels via specific chemorepellent effects on the lymphatic endothelial monolayer, an event linked with distant LN metastasis. 150 Thus, specific vascular responses within the SLN may provide additional prognostic information regarding tumor progression.
VASCULAR REMODELING EN ROUTE TO METASTASIS
There is little literature on modification of large blood and lymphatic vessels that participate in transport of tumor cells to metastatic sites, representing an untapped area of potential intervention. Feeder arteries and draining veins of tumors are commonly dilated and tortuous. 33, 153 In inflammatory settings, eNOS is seen to regulate dilation of LN feeder arterioles; a similar mechanism may operate in tumors. 154 Studies of large collecting lymphatics indicate that dilation of these vessels, induced by lymphangiogenic growth factors, enhances transport of tumor cells. 155 This dilation is mediated via prostaglandins produced by local ECs. 68 
VASCULAR REMODELING AT THE METASTATIC SITE
The 'soil and seed' hypothesis put forward by Paget 156 over 100 years ago suggests that there are preferred sites for growth of metastatic tumor cells. Although this 'soil' may be dependent on molecular signals, including chemokines and growth factors, the properties and molecular profiles of ECs in these locations are critical for organ entry, extravasation and the survival and growth of metastatic tumor cells. The more recent description of a 'premetastastic niche' suggests a permissive microenvironment capable of supporting metastatic cells. 157, 158 This microenvironment could include increased blood and lymphatic vessel density, promoted by secreted growth factors, such as VEGF-A, VEGF-C and VEGF-D, and the presence of BMD VEGFR-1 þ endothelial precursors. 130, 147, 159, 160 Although soluble factors and cells derived from distant tissues have been implicated in establishing the pre-metastatic niche, there is an emerging concept of tumor-derived exosomes, which can educate bone marrow and metastatic sites to receive and support the growth of tumor cells. 161, 162 These exosomes appear to contain both DNA and protein components, and have a molecular-and organtargeting specificity, as had been shown recently for melanoma and renal cancer stem cells. 162, 163 VASCULAR REMODELING DURING CANCER TREATMENT Various antiangiogenic drugs have been developed over the past 15 years, targeting ligands and receptors that regulate angiogenesis in tumors, in particular the VEGF-A/VEGFR-2 signaling axis. 164 These include monoclonal antibodies, soluble receptor domains and small molecule kinase inhibitors with varying specificity towards angiogenic signaling pathways. The best studied antiangiogenic drug is the humanized monoclonal antibody Bevacizumab (also known as Avastin), targeting VEGF-A, which is The process of vascular normalization has been described to account for some of the effects of anti-angiogenic treatment. Although the normal vascular bed ('Normal') has a regular appearance, with defined arterial and venous segments connected through a capillary bed, the 'abnormal' appearance of the 'tumor-induced' vascular bed is consistent with dysregulated but active angiogenesis and vessel remodeling through the activation of various signaling pathways, including the VEGF-A/VEGFR-2 axis. These vessels are often poorly formed, show high vascular permeability and have reduced pericyte coverage. This disorganized structure causes chaotic blood flow and poor tissue perfusion, often leading to regions of hypoxia and potentially impaired access for drugs. Within the tumor the distinction between the arterial and venous side is difficult to distinguish. In the 'normalized' tumor that has been treated with an anti-angiogenic agent, the vasculature resembles more its original structure. There is pruning of the tiny induced microvessels in the tumor, whereas enlarged vessels can show little change. 177 This normalized vasculature potentially allows better access of chemotherapeutic drugs to tumor cells. most commonly used in combination with cytotoxic chemotherapy. [164] [165] [166] [167] Although the theory behind targeting tumor angiogenesis was originally based on preventing the growth of blood vessels to 'starve' the tumor, the mechanisms by which antiangiogenic drugs elicit their effects in cancer may be more complex. 24, 93 The concept that antiangiogenic drugs induce 'normalization' of the tumor vasculature ( Figure 3 ) has gained favor based on experimental and patient-derived data. 24, 77, 168, 169 According to this concept, heterogeneous and leaky tumor blood vessels, which function poorly, regain some degree of their normal architecture, potentially allowing chemotherapeutic drugs better access to tumor cells.
An issue that has arisen with antiangiogenic agents, such as Bevacizumab, is the development of drug resistance. Cancer patients treated with Bevacizumab either do not respond to the drug or develop resistance over time. 170 This suggests that tumors can utilize alternative signaling mechanisms to promote angiogenesis, which is not surprising given the diversity of proangiogenic proteins. Candidate molecules that may induce tumor angiogenesis when VEGF-A is blocked by Bevacizumab include VEGF-C 65, 171 and VEGF-D, 172, 173 which, when proteolytically processed, can activate VEGFR-2. 171, 174, 175 Further, other ligand/ receptor systems, such as fibroblast growth factor/fibroblast growth factor receptor and Angiopoietin/Tie-2, may be capable of driving angiogenesis in cancer. 176 Emerging evidence also suggests that antiangiogenesis-induced tumor hypoxia may recruit increased numbers of pro-angiogenic BMD cells that can facilitate revascularization. 81, 86, 169 Co-option of existing vessels is a further alternative mechanism whereby a tumor could obtain more blood supply during bevacizumab treatment. 81 In a glioma model in the absence of chemotherapy, effective vascular normalization via bevacizumab alone was insufficient to slow tumor growth; although small vessels were pruned, large vessels persisted that may have been sufficient to sustain the tumor through various mechanisms. 177 Pericytes are also likely to have an important role in the sensitivity of blood vessels to antiangiogenic drugs. 76, 81 Exploration of these and other pathways in cancer may uncover mechanisms of resistance to current antiangiogenic drugs and indicate combinations of drugs that provide enhanced clinical benefits. 170 Moreover, such studies should facilitate more focused use of currently available agents on subsets of cancer patients who are more likely to respond to these drugs.
DISCUSSION AND CONCLUSIONS
Although advances in EC biology and antiangiogenic therapies have shed light on vascular remodeling in cancer, we are likely only scratching the surface of this complex field. The remodeling of the vasculature is a key response to the formation of a tumor, and it is clear that the complex array of factors secreted by tumor cells or stromal components alter normal vascular structures. What is not clear is which of these changes are pivotal to the growth of the primary tumor and its eventual spread to distant organs. Although antiangiogenic therapies have provided benefit to some patients, this experience has also taught us that there is a complexity to the use of these agents, in part because of the adaptive response of the tumor to find different signaling pathways to drive angiogenesis. Understanding the nature of resistance to antiangiogenic therapies and linking the features of vascular remodeling in human pathologies to changes in functional signaling pathways will provide new insight into how changes to the vasculature can perpetuate diseases such as cancer.
ABBREVIATIONS BMD, bone marrow-derived; EC, endothelial cell; EPC, endothelial progenitor cell; HEV, high endothelial venule; LN, lymph node; SLN, sentinel LN; VEGF, vascular endothelial growth factor
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